Affimed (AFMDQ)

OTHER OTC:AFMDQ

AFMDQ

Affimed

RESEARCH TOOLSreports

Affimed (AFMDQ) Price & Analysis

Compare

848 Followers

AFMDQ Stock Chart & Stats

$0.02

Market closed

$0.02

Day’s Range― - ―

52-Week Range$0.01 - $2.92

Previous CloseN/A

VolumeN/A

Average Volume (3M)53.30K

Market Cap

$1.52K

Enterprise Value-$19.18M

Total Cash (Recent Filing)$24.94M

Total Debt (Recent Filing)$12.89M

Price to Earnings (P/E)―

Beta15.39

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding15,227,463

10 Day Avg. Volume6,362

30 Day Avg. Volume53,296

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)1.46

Price to Sales (P/S)10.21

P/FCF Ratio-0.74

Enterprise Value/Market Cap-12.59K

Enterprise Value/Revenue-21.87

Enterprise Value/Gross Profit-21.87

Enterprise Value/Ebitda0.29

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Potential PartnershipUpcoming presentation at a major oncology meeting presents a potential opportunity to attract partners or funding.

Bears Say

Insolvency ProceedingsAffimed announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.

Liquidity ConcernsThere is substantial doubt about the company's ability to continue as a going concern due to liquidity conditions.

Stock Trading SuspensionFiling for the insolvency proceedings results in Affimed’s common shares being suspended from trading on, and subsequent delisting from The Nasdaq Global Market.

AFMDQ FAQ

What was Affimed’s price range in the past 12 months?

Affimed lowest stock price was $0.01 and its highest was $2.92 in the past 12 months.

What is Affimed’s market cap?

Affimed’s market cap is $1.52K.

When is Affimed’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Affimed’s earnings last quarter?

Currently, no data Available

Is Affimed overvalued?

According to Wall Street analysts Affimed’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Affimed pay dividends?

Affimed does not currently pay dividends.

What is Affimed’s EPS estimate?

Affimed’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Affimed have?

Affimed has 15,227,463 shares outstanding.

What happened to Affimed’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Affimed?

Currently, no hedge funds are holding shares in AFMDQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.